Low Weight Heparin prOphylaxis for Placental-Mediated Complications of PrEgnancy

PHASE3CompletedINTERVENTIONAL
Enrollment

361

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2016

Conditions
High Risk Pregnant WomenPlacental InsufficiencyPreeclampsia
Interventions
DRUG

Enoxaparin

40 mg (4000 IU) women \<80 kg at the time of randomization or 60 mg (6000 IU) women\> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.

Trial Locations (4)

48903

Hospital de Cruces, Barakaldo

08035

Hospital Universitario Vall d'Hebron, Barcelona

08950

Hospital Sant Joan de Deu, Esplugues de Llobregat

08830

Parc sanitari Sant Joan de Deu, Sant Boi de Llobregat

All Listed Sponsors
collaborator

Hospital Vall d'Hebron

OTHER

collaborator

Hospital Sant Joan de Deu

OTHER

collaborator

Hospital de Cruces

OTHER

collaborator

Parc Sanitari Sant Joan de Déu

OTHER

lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT01388322 - Low Weight Heparin prOphylaxis for Placental-Mediated Complications of PrEgnancy | Biotech Hunter | Biotech Hunter